Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

BRCA1/2 Mutation × 30 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 498 Neoplasms 433 Carcinoma, Non-Small-Cell Lung 380 Prostatic Neoplasms 321 Lung Neoplasms 244 Colorectal Neoplasms 234 Neoplasm Metastasis 197 Leukemia, Myeloid, Acute 192 Multiple Myeloma 185 Ovarian Neoplasms 171 Melanoma 165 Pancreatic Neoplasms 139 Squamous Cell Carcinoma of Head and Neck 119 Brain Neoplasms 115 Recurrence 114 Lymphoma 109 Carcinoma, Hepatocellular 109 Glioblastoma 100 Endometrial Neoplasms 100 Urinary Bladder Neoplasms 98 Triple Negative Breast Neoplasms 98 Stomach Neoplasms 97 Uterine Cervical Neoplasms 96 Glioma 96 Carcinoma, Renal Cell 96 Precursor Cell Lymphoblastic Leukemia-Lymphoma 92 Lymphoma, Non-Hodgkin 88 Hematologic Neoplasms 82 Head and Neck Neoplasms 82 Sarcoma 81

Interventions

rocakinogene sifuplasmid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04367675 2026-02-23

INO 5401 Vaccination in BRCA1/2 Mutation Carriers

Abramson Cancer Center at Penn Medicine

Phase 1 Active not recruiting

BRCA1/2 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon ⚡